Stockreport

Pharvaris Presents Deucrictibant Long-Term Extension Data for Both the Prophylactic and On-Demand Treatment of HAE at the Bradykinin Symposium 2024 [Yahoo! Finance]

Pharvaris N.V. - Ordinary Shares  (PHVS) 
PDF Long-term prophylaxis extension data of deucrictibant shows attack reduction is maintained for over one year; open-label extension participants experienced a 93% reduct [Read more]